Get the Stockscreener App
1.00
11.50%
-0.13
After Hours:
1.02
0.02
+2.00%
Humacyte Inc stock is traded at $1.00, with a volume of 10.07M.
It is down -11.50% in the last 24 hours and up +44.70% over the past month.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.13
Open:
$1.15
24h Volume:
10.07M
Relative Volume:
1.45
Market Cap:
$222.02M
Revenue:
$2.04M
Net Income/Loss:
$-43.21M
P/E Ratio:
-4.8379
EPS:
-0.2067
Net Cash Flow:
$-105.93M
1W Performance:
-7.41%
1M Performance:
+44.70%
6M Performance:
-18.70%
1Y Performance:
-46.52%
1-Day Range:
$1.00
$1.22
1-Week Range:
$0.86
$1.22
52-Week Range:
$0.5469
$2.93
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.00 | 250.88M | 2.04M | -43.21M | -105.93M | -0.2067 |
VRTX
Vertex Pharmaceuticals Inc
|
450.41 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.87 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
822.13 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.45 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.47 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Does Humacyte’s (HUMA) Nasdaq Notice Quietly Reframe Its Financing Flexibility And Clinical Adoption Story? - simplywall.st
Humacyte, Inc. (NASDAQ:HUMA) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright reiterates Humacyte stock rating at buy, $3 target - Investing.com
H.C. Wainwright reiterates Humacyte stock rating at buy, $3 target By Investing.com - Investing.com Canada
Barclays Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
HUMACYTE ($HUMA) Releases Q1 2026 Earnings - Moomoo
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $1.5 - Moomoo
Humacyte (NASDAQ: HUMA) posts Q1 2026 loss and flags going concern risk - Stock Titan
Humacyte, Inc. Stock 12‑Month Price Target Cut to $4.93, Implies 442% Upside - TradingView
Humacyte (HUMA) Q1 2026 Earnings Transcript - The Globe and Mail
MSN Money - MSN
Humacyte Q1 2026 Earnings Call Transcript - MarketBeat
BTIG cuts Humacyte stock price target on revenue miss, slower ramp - Investing.com
HUMA: Symvess sales surged, restructuring cut costs, and key clinical milestones are on track for 2026 - TradingView
Humacyte Releases Q1 2026 Financial Results - AlphaStreet
Humacyte Q1 Earnings Call Highlights - Barchart.com
Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript - Yahoo Finance
Earnings call transcript: Humacyte Q1 2026 EPS beats forecast, revenue misses - Investing.com
HUMA: Symvess sales surged year-over-year, with restructuring and global expansion positioning for growth - TradingView
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
HUMA: Symvess sales grew, net loss widened, and restructuring cut costs as global expansion advanced - TradingView
Bioengineered blood vessel firm wins Saudi deal and Pentagon backing - Stock Titan
Humacyte Inc (HUMA) Q1 2026 Earnings Call Highlights: Sales Surge and Strategic Expansions Amid ... By GuruFocus - Investing.com Canada
Humacyte appoints Todd Rasmussen as chief surgical officer By Investing.com - Investing.com South Africa
Humacyte appoints Dr. Todd E. Rasmussen as chief surgical officer - marketscreener.com
Humacyte appoints Todd Rasmussen as chief surgical officer - Investing.com
Humacyte Appoints Todd E. Rasmussen, M.D., as Chief Surgical Officer to Advance Clinical Adoption of Symvess - Quiver Quantitative
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer - The Manila Times
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer - GlobeNewswire Inc.
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Humacyte Receives Nasdaq Notice on Minimum Bid Requirement - The Globe and Mail
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):